Our team has always been committed to the clinical application of our project, which will be used as a new method of cancer treatment, together with other traditional cancer treatment methods, for future cancer treatment.
Obviously, our project only studied the combination of three star targets in the treatment of NSCLC. In future research, other researchers can follow our ideas of hepatocyte transfection (smaller immune side effects, better biocompatibility, longer-term drug efficacy), continue to study other cancers and their feasible gene therapy strategies, and develop more drugs for gene therapy (and even reduce the cost of gene therapy for cancer through our methods).
We plan to work with some well-known pharmaceutical companies and scientific research teams to further promote our cancer treatment strategy with synthetic biological ideas in the real world, and even develop drugs that can be taken by patients.
Of course, the implementation of our project also needs to consider a lot of security issues. In our laboratory work, we have designed a model to determine the optimal concentration of the drug to reduce the damage to the body. At the same time, we plan to detect the effect of siRNA expressed by siRNA plasmid on hepa1-6 cell mRNA, the effect of KIBRA overexpression on hepatocytes, and the effect of lentiviral vector injection on mice (especially liver cell apoptosis) to verify the safety of our experiment.
The biggest problem facing our project is the issue of efficacy. Although our combination therapy for cancer and the smaller immune side effects brought by self editing and self-assembly in vivo have brought great advantages to our final patent medicine, the specific drug efficacy, the comparison with other cancer treatment methods, and even the evaluation of patient acceptance and price need to be further tested by laboratory, market and relevant government departments.